Publicaciones en colaboración con investigadores/as de Hospital Ramón y Cajal (31)

2023

  1. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

    Prostate, Vol. 83, Núm. 4, pp. 376-384

  2. Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma

    Cancers, Vol. 15, Núm. 11

2022

  1. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

    European Journal of Cancer, Vol. 175, pp. 110-119

  2. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

    Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34

  3. Erratum: A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial (Oncotarget. (2020) 11 (4457–4462) DOI: 10.18632/oncotarget.27807)

    Oncotarget

  4. Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer

    Cancers, Vol. 14, Núm. 2

  5. Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study

    European Journal of Cancer, Vol. 172, pp. 340-348

  6. Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study

    ESMO Open, Vol. 7, Núm. 5

  7. Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy

    Journal of Clinical Medicine, Vol. 11, Núm. 3

  8. Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy

    ESMO Open, Vol. 7, Núm. 2

2021

  1. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies

    Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 882-891

2020

  1. A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial

    Oncotarget, Vol. 11, Núm. 47, pp. 4457-4462

  2. Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer[Formula presented]

    European Urology, Vol. 77, Núm. 2, pp. 269-276

  3. Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma

    European Journal of Cancer, Vol. 138, pp. 202-211

2018

  1. Efficacy of therapies after progression to up-front docetaxel (D) with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii286

  2. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)

    Oncologist, Vol. 23, Núm. 4, pp. 422-432

  3. Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii286

2017

  1. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study

    Annals of Oncology, Vol. 28, Núm. 7, pp. 1-9

  2. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib

    Scientific Reports, Vol. 7

  3. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97